SHR-4602

DRUG4 trials

Conditions

Advanced Solid TumorsBreast CancerBreast NeoplasmBreast TumorsEarly-stage Breast CancerHER2-expressing or -Mutated Unresectable or Metastatic Solid TumorsHER2-expressing or HER2-mutated Locally or Metastatic Solid TumorsHER2-negative Breast Cancer

Phase 1

A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors

WithdrawnNCT06560138

Atridia Pty Ltd.HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors

Start: 2025-03-01End: 2026-09-12Updated: 2025-01-07

Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

RecruitingNCT05582499

Fudan UniversityBreast Cancer, Breast Neoplasm, Breast Tumors +7

Start: 2022-11-01End: 2028-09-30Target: 716Updated: 2025-08-22

SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors

Not yet recruitingNCT06516926

Jiangsu HengRui Medicine Co., Ltd.HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors

Start: 2024-08-31End: 2026-12-31Target: 240Updated: 2024-07-24

A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors

Not yet recruitingNCT06704828

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Solid Tumors

Start: 2024-12-31End: 2027-04-30Target: 20Updated: 2024-11-26

Clinical Cancer Research2025-06-13

Abstract P2-11-06: Neoadjuvant chemotherapy plus camrelizumab vs. chemotherapy in patients with locally advanced immunomodulatory triple-negative breast cancer: a prospective, randomized, open-label, phase 2 trial

Clinical Cancer Research2025-06-13

Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial

Therapeutic Advances in Medical Oncology2024-01-017 citations

SHR-4602

Sponsors

Conditions

Phase 1

Phase 2

Related Papers